Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

2.6%

1 terminated/withdrawn out of 38 trials

Success Rate

97.4%

+10.9% vs industry average

Late-Stage Pipeline

34%

13 trials in Phase 3/4

Results Transparency

62%

23 of 37 completed trials have results

Key Signals

23 with results

Enrollment Performance

Analytics

Phase 2

18(48.6%)

Phase 3

11(29.7%)

Phase 1

5(13.5%)

Phase 4

2(5.4%)

N/A

1(2.7%)

37Total

Phase 2(18)

Phase 3(11)

Phase 1(5)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials

NCT05493111Phase 3Completed

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

Role: lead

NCT05360966Phase 3Completed

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Role: lead

NCT05285644Phase 3Completed

Study Evaluating the Safety and Efficacy of AR-15512

Role: lead

NCT04498182Phase 2Completed

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

Role: lead

NCT05283395Phase 4Completed

Rocklatan® Evaluation

Role: lead

NCT01699464Phase 2Completed

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Role: lead

NCT01997879Phase 1Completed

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

Role: lead

NCT04620135Phase 3Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT03835884Phase 1Completed

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Role: lead

NCT04498169Phase 2Completed

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

Role: lead

NCT05497479Phase 1Completed

Study Evaluating Techniques for Measuring Tear Production

Role: lead

NCT04064918Not ApplicableWithdrawn

Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity

Role: collaborator

NCT04401982Completed

Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

Role: collaborator

NCT03739593Phase 2Completed

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Role: lead

NCT03284853Phase 3Completed

Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT03844945Phase 2Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Role: lead

NCT03808688Phase 4Completed

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Role: lead

NCT03310580Phase 2Completed

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

Role: lead

NCT03233308Phase 2Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Role: lead

NCT02558400Phase 3Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Role: lead